Last reviewed · How we verify
GOSERELIN
At a glance
| Generic name | GOSERELIN |
|---|---|
| Modality | Recombinant protein |
| Phase | FDA-approved |
| First approval | 1989 |
Approved indications
Common side effects
- Hot flashes/Hot flushes
- Diarrhea
- Sexual dysfunction
- Decreased erections
- Headache
- Sweating
- Acne
- Emotional lability
- Depression
- Decreased libido
- Vaginitis
- Breast atrophy
Serious adverse events
- Tumor flare phenomenon
- Spinal cord compression
- Ureteral obstruction
- Myocardial infarction
- Cerebrovascular accident
- Scrotal infection
- Scrotal hematoma
- Skin necrosis
- Renal insufficiency
- Urinary obstruction
Key clinical trials
- A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer (PHASE2)
- A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma (PHASE2)
- Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients (PHASE2)
- Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study (PHASE3)
- Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (PHASE2, PHASE3)
- Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery. (NA)
- Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer (PHASE2)
- Radiotherapy After Prostatectomy for Node Positive Prostate Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GOSERELIN CI brief — competitive landscape report
- GOSERELIN updates RSS · CI watch RSS